Alacovir

Alacovir

abacavir + lamivudine

Manufacturer:

GPO

Distributor:

GPO
Concise Prescribing Info
Contents
Abacavir sulfate 600 mg, lamivudine 300 mg
Indications/Uses
HIV-1 infection in combination w/ other antiretroviral agents.
Dosage/Direction for Use
Adult 1 tab daily in combination w/ other antiretroviral agents.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Hepatic impairment.
Special Precautions
Serious & sometimes fatal hypersensitivity reactions. Permanently discontinue if hypersensitivity cannot be ruled out. Lactic acidosis & severe hepatomegaly w/ steatosis. Closely monitor hepatic function w/ clinical & lab follow-up for at least several mth in patients who discontinue treatment & are coinfected w/ HIV-1 & HBV. Patients w/ or w/ no known risk factors for liver diseases. Immune reconstitution syndrome; fat redistribution/accumulation; risk of CHD. Emergence of lamivudine-resistant HBV. Patients w/ CrCl <50 mL/min. Contraindicated in hepatic impairment. Pregnancy. Do not breastfeed during treatment. Ped <18 yr.
Adverse Reactions
Abnormal dreams, anxiety, depression/depressed mood, dizziness/vertigo, fatigue/malaise, headache/migraine, insomnia; abdominal pain/gastritis, diarrhea, nausea; drug hypersensitivity, pyrexia, rash.
Drug Interactions
Decreased abacavir elimination w/ ethanol. Hepatic decompensation in HIV/HCV coinfected patients w/ interferon alfa, w/ or w/o ribavirin. Increase clearance of methadone. Decreased bioavailability w/ methadone. Increased lamivudine area under the curve (AUC) w/ nelfinavir & trimethoprim/sulfamethoxazole. Reduced lamivudine phosphorylation w/ ribavirin.
MIMS Class
ATC Classification
J05AR02 - lamivudine and abacavir ; Belongs to the class of antivirals for treatment of HIV infections, combinations.
Presentation/Packing
Form
Alacovir FC tab
Packing/Price
3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in